David Guyer

Dr. Guyer re-joined SV Life Sciences, a venture capital firm focused on healthcare, in 2021 as venture partner where he has previously been both venture partner and partner from 2006 to 2013 until he founded Ophthotech (now Iveric Bio), a biotech focused on the discovery and development of treatments for retinal diseases.

Dr. Guyer also co-founded Eyetech Pharmaceuticals Inc. and served as its Chief Executive Officer and as a member of its Board of Directors from 2000 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. Prior to co-founding Eyetech Pharmaceuticals, Dr. Guyer was a professor and served as Chairman of the Department of Ophthalmology at New York University School of Medicine.

Dr. Guyer received a B.S. from Yale College and an M.D. from Johns Hopkins Medical School. Dr. Guyer completed his ophthalmology residency at Wilmer Ophthalmological Institute, Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.